Transitioning HBV cure programs into multiple late-stage combination studies with interim results t...
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and roy...
DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited
2024-01-03 20:00
4621
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased an...
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased an...
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at ...
First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HB...
Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to ac...
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in ...
Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to tre...
Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatm...
BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potent...
Brii Bio receives an "A" grade in the latest MSCI ESG Rating DURHAM, N.C. and BEIJING, April 28, 20...
Company maintains priority focus on clinical programs to develop a novel f unctional cure for hepati...
Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination st...
* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated ...
* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable phar...
Addition increases diversity of Board governance and supports further independent expertise DURHAM...
Additions to executive team strengthen global leadership and position Company for strategic long-te...
Building a leadership team with global and local experience and expertise to enable rapid execution...